Using AI to automate clinical microbiology
Australian Government grant initiative. Research and Development Tax Incentives - Customer Story on LBT Innovations
Extraordinary General Meeting Presentation 2018
Presentation by Brent Barnes Chief Executive Officer & Managing Director of LBT Innovations at this April's Extraordinary General Meeting
Artificial Intelligence for Pathology Bottlenecks
LBT’s APAS® received regulatory approval and patents over the last 18 months. Its first evaluation trial at St Vincent Hospital was successfully completed.
APAS Installed at First Hospital Site
Bioshares Analyst Report following LBT Innovations installation of its first APAS Independence instrument in Melbourne, at St Vincent's Hospital.
Under The Radar Report Small CAP Research
Robotics is a hot investment theme and LBT has been riding the wave of interest with its device to automate the processing and analysis of biological samples.
Under The Radar Report Small CAP Research
Under the Radar Report Biotech Special - Tim Boreham's sector run-down on opportunities to make money from the makers of devices and diagnostic tools.
Cornerstone-type Investor to Help Develop WoundVue
WoundVue is a hand-held device capable of interpreting tissue types and providing surface area, volume and depth measurements.
APAS Reaches Self Certification
LBT Innovations has completed the self-certification process for CE Marking for its APAS Independence launching by year’s end.
Dr Boreham’s Crucible Biotech Dailly
"The challenge lies with the regulatory pathway and what product claims you want to make." said Brent Barnes, CEO of LBT Innovations
APAS Independence Unveiled
The working APAS Independence will be showcased at a major clinical microbiology conference next month, and launched by end of 2017.
An Exceptional Share Price Increase
Share price surged by 358% percent this week, following announcement of the receipt of clearance from the FDA for The Automatic Plate Assessment System (APAS).